The pathways that we identified as modulated by IFNβ treatment suggest that IFNβ treatment most likely recruits viral infection response pathways with highly targeted, cell-specific effects to reduce overall inflammation, resulting in reduced relapses and disease activity. The gene discussed is IFNB1; the disease is viral infectious disease.